- 期刊
抗藥性結核病治療新趨勢
The New Trend of Clinical Management of Multidrug-Resistant and Extensively Drug- Resistant Tuberculosis
摘要
全球的多重抗藥性結核病(multidrug-resistant tuberculosis, MDR-TB)與廣泛抗藥性結核病(extensively drug-resistant tuberculosis, XDR-TB)迅速蔓延。儘管全球結核病進一步取得了控制，但MDR-TB與XDR-TB患者的疾病負擔和治療結果幾乎沒有變化。2016年，世界衛生組織(World Health Organization, WHO)發布了抗藥性結核病管理新準則，旨在以快速的分子檢測提高檢測率，和以短期治療處方治療抗藥性結核病，使治療效果更好。新藥bedaquiline及delamanid的開發與新的藥物分類也加入抗藥性結核病治療指引，以期達到治療抗藥性結核病成功的結果。
並列摘要
The multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) are spreading worldwide. Although MDR-TB had been controlled, but the disease burden and treatment outcome in patient with MDR-TB had remained virtually unchanged. In 2016, The World Health Organization published a new guideline for drug-resistant tuberculosis treatment. This guideline intended to use rapid molecular tests to improve the detection rate and short-term regimens to treat drug-resistant tuberculosis to achieve a better treatment effect. In order to achieve a successful treatment of drug-resistant tuberculosis, the new drugs developing, bedaquiline and delamanid, and new classifications of anti-TB drugs applicability were included in new guideline for drug-resistant TB treatment.
延伸閱讀
- 陳義龍、許嘉裕、曾誠齊（2003）。結核菌感染治療藥物的發展。化學，61(4)，599-609。https://doi.org/10.6623/chem.2003056
- 孫幸筠（2021）。抗結核藥物的新進展。愛之關懷季刊，(116)，3-7。https://www.airitilibrary.com/Article/Detail?DocID=a0000410-202109-202112140021-202112140021-3-7
- 黃紹宗、黃瑞明、桑淑華、黃素玲（2007）。廣泛抗藥性結核菌－結核病治療新威脅。感染控制雜誌，17(2)，80-89。https://doi.org/10.6526/ICJ.200704_17(2).0002
- 陳卉溱（2013）。診斷、治療及預防抗藥性結核病。嘉基藥訊，(105)，4-6。https://www.airitilibrary.com/Article/Detail?DocID=a0000124-201305-201312120029-201312120029-4-6
- Chou, T. K., & Huang, R. M. (2007). Multidrug-resistant Tuberculosis. Epidemiology Bulletin, 23(3), 84-85. https://doi.org/10.6525/TEB.200703_23(3).0003